Seventeen SNPs were taken forward to stage 2 in up to 4,900 and 4,891 individuals from the upper and lower tails of BMI, respectively. Ten SNPs reached genome-wide significance (P<5×10-8) in the joint meta-analysis of stage 1 and stage 2, but all had been previously identified as loci associated with BMI in the general population.4 A total of 118 SNPs were included in stage 2 for clinical classes of obesity, which included up to 1,162 cases and 22,307 controls for obesity class III, and 65,332 cases and 39,294 controls for overweight. Of the 62 SNPs that showed P<5×10-8 in the joint meta-analyses for at least one obesity class (Supplementary Table 6), seven were novel, explaining an additional 0.09% of the variability in BMI (Supplementary Table 7). These included one locus for overweight (RPTOR), three loci for obesity class I (GNAT2, MRPS33P4, ADCY9), two loci for obesity class II (HS6ST3, ZZZ3), and one locus associated with both overweight and obesity class I (HNF4G) (Table 1, Supplementary Fig. 5-7). Although these loci were identified for specific clinical classes of obesity, all novel
